This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Leiden Nonischemic Cardiomyopathy Study

This study is currently recruiting participants.
See Contacts and Locations
Verified December 2016 by Katja Zeppenfeld, Leiden University Medical Center
Sponsor:
Information provided by (Responsible Party):
Katja Zeppenfeld, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT01940081
First received: August 29, 2013
Last updated: December 29, 2016
Last verified: December 2016
  Purpose

Rationale: Sudden cardiac death, mainly caused by ventricular arrhythmias (VA), is a major cause of morbidity and mortality in non-ischemic cardiomyopathy (NICM). Therapies that effectively prevent VA are lacking. Improved understanding of the substrate and mechanisms of VA in NICM may allow more effective, individualized and substrate-based therapies to be developed. In addition, risk stratification in NICM needs to be improved so that therapies can be allocated more efficiently.

Objectives: 1) To improve our understanding of the underlying pro-arrhythmic substrate and electrophysiologic mechanisms of VA in NICM, and to develop individualized treatment for VA based on the identified substrate. 2) To improve risk stratification for VA and sudden cardiac death in NICM based on substrate characteristics. 3) to evaluate disease progression in NICM.

Hypothesis: Improved understanding of the substrate and mechanisms of VA in NICM may allow more effective, individualized and substrate-based therapies to be developed.

Study design: A prospective cohort study.

Study population: The study population will consist of three groups (A, B and C): NICM patients with documented VA, suspected VA or intermediate to high risk for VA (according to established criteria) who are not referred for cardiac surgery (group A), NICM patients with documented VA, suspected VA or a high risk for VA who are referred for cardiac surgery (group B) and a control group consisting of patients without NICM who are referred for cardiac surgery (group C).

Evaluation: All patients will be evaluated according to current standards for patients with NICM. Evaluation will include 24h-Holter, echocardiography, coronary angiogram and contrast-enhanced MRI (CE-MRI). If CE-MRI is performed in another hospital, additional recordings will be performed in our hospital. Additionally, blood samples (arterial, cardiac venous and peripheral venous) for collagen turnover markers will be taken from all patients. 123-iodine metaiodobenzylguanidine (123-I MIBG) imaging, electrophysiologic study and endomyocardial biopsy will be performed in group A and B. Intra-operative biopsy will be performed in group B and C.

Intervention: In group B, intra-operative mapping and cryo-ablation and postoperative electrophysiologic study will be performed in patients with subepicardial late enhancement on MRI or induced VA suspected for an subepicardial origin.

Main study parameters/endpoints: The main study parameters are extent, location and pattern of fibrosis on imaging and in biopsy specimens. The main study endpoints are inducibility of VA, type of induced VA, spontaneous VA and type of spontaneous VA.


Condition Intervention
Cardiomyopathy, Dilated Tachycardia, Ventricular Ventricular Fibrillation Other: Transthoracic echocardiography Other: Exercise test Other: 24-hour Holter electrocardiogram Other: Contrast-enhanced magnetic resonance imaging Other: 123-iodine metaiodobenzylguanidine imaging Other: Blood samples Genetic: Genetic analysis Procedure: Invasive electrophysiological study Procedure: Endomyocardial biopsy Procedure: Intraoperative biopsy Procedure: Intraoperative mapping and/or ablation

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Leiden Nonischemic Cardiomyopathy Study

Resource links provided by NLM:


Further study details as provided by Katja Zeppenfeld, Leiden University Medical Center:

Primary Outcome Measures:
  • Inducibility of ventricular arrhythmias [ Time Frame: Baseline electrophysiological study ]
  • Type of induced ventricular arrhythmias [ Time Frame: Baseline electrophysiological study ]
  • Spontaneous ventricular arrhythmias [ Time Frame: Up to 10 years ]
  • Type of spontaneous ventricular arrhythmias [ Time Frame: Up to 10 years ]

Secondary Outcome Measures:
  • Hospital admissions for heart failure [ Time Frame: Up to 10 years ]
  • Cardiac mortality [ Time Frame: Up to 10 years ]
  • All-cause mortality [ Time Frame: Up to 10 years ]
  • LV function/dimensions/compact fibrosis deterioration as assessed by 123-I MIBG imaging and/or CE-MRI [ Time Frame: 18 months ]

Biospecimen Retention:   Samples With DNA

Per patient:

Blood samples (40 mL) Ventricular biopsies


Estimated Enrollment: 220
Study Start Date: October 2011
Estimated Study Completion Date: October 2021
Estimated Primary Completion Date: October 2021 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group A: Nonischemic cardiomyopathy - not admitted for surgery

Patients with nonischemic cardiomyopathy with:

  • documented ventricular arrhythmia or
  • suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
  • high risk for ventricular arrhythmia (LVEF ≤ 35%) or
  • intermediate risk for ventricular arrhythmia (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)

who are not admitted for cardiac surgery

Other: Transthoracic echocardiography Other: Exercise test Other: 24-hour Holter electrocardiogram Other: Contrast-enhanced magnetic resonance imaging Other: 123-iodine metaiodobenzylguanidine imaging Other: Blood samples Genetic: Genetic analysis Procedure: Invasive electrophysiological study Procedure: Endomyocardial biopsy
Group B: Nonischemic cardiomyopathy -admitted for surgery

Patients with nonischemic cardiomyopathy with:

  • documented ventricular arrhythmia or
  • suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or
  • high risk for ventricular arrhythmia (LVEF ≤ 35%)

who are admitted for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)

Other: Transthoracic echocardiography Other: Exercise test Other: 24-hour Holter electrocardiogram Other: Contrast-enhanced magnetic resonance imaging Other: 123-iodine metaiodobenzylguanidine imaging Other: Blood samples Genetic: Genetic analysis Procedure: Invasive electrophysiological study Procedure: Intraoperative biopsy Procedure: Intraoperative mapping and/or ablation
Group C: Controls

Patients without nonischemic cardiomyopathy (controls) who are admitted for:

  • Coronary artery bypass graft surgery and who do not have prior myocardial infarction
  • Aortic valve replacement
Other: Transthoracic echocardiography Other: Exercise test Other: 24-hour Holter electrocardiogram Other: Contrast-enhanced magnetic resonance imaging Other: Blood samples Procedure: Intraoperative biopsy

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with nonischemic cardiomyopathy and controls who are admitted to the hospital
Criteria

Inclusion criteria, group A:

  • Nonischemic cardiomyopathy
  • Documented ventricular arrhythmia, suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or high risk for ventricular arrhythmias (LVEF ≤ 35%) or intermediate risk for ventricular arrhythmias (LVEF ≤ 50% and late enhancement on contrast-enhanced MRI)
  • Admission not for cardiac surgery

Inclusion criteria, group B:

  • Nonischemic cardiomyopathy
  • Documented ventricular arrhythmia or suspected ventricular arrhythmia (e.g. because of out-of-hospital cardiac arrest, palpitations or syncope) or high risk for ventricular arrhythmia (LVEF ≤ 35%)
  • Admission for cardiac surgery (e.g., mitral valve annuloplasty or CorCap)

Inclusion criteria, group C:

- Patients undergoing aortic valve replacement or coronary artery bypass graft surgery

Exclusion criteria, all groups:

  • Age < 18 years or > 80 years
  • Inadequate patient competence
  • Pregnancy
  • Inability to comply with the protocol due to haemodynamic instability

Exclusion Criteria, groups A and B:

- Other cardiomyopathy (e.g., prior myocardial infarction, infiltrative cardiac disease such as sarcoidosis, amyloidosis or Chagas cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy/dysplasia, hypertrophic cardiomyopathy, non-compaction cardiomyopathy and congenital heart disease)

Exclusion criteria, group C:

  • Nonischemic cardiomyopathy
  • Prior myocardial infarction
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01940081

Locations
Netherlands
Dept. of Cardiology, Leiden University Medical Center Recruiting
Leiden, Netherlands
Contact: K Zeppenfeld, MD, PhD    0031715266933    k.zeppenfeld@lumc.nl   
Principal Investigator: Katja Zeppenfeld, MD, PhD         
Sub-Investigator: Sebastiaan Piers, MD         
Sponsors and Collaborators
Leiden University Medical Center
  More Information

Responsible Party: Katja Zeppenfeld, Prof. dr., Leiden University Medical Center
ClinicalTrials.gov Identifier: NCT01940081     History of Changes
Other Study ID Numbers: Cardiomyopathy study
Study First Received: August 29, 2013
Last Updated: December 29, 2016

Keywords provided by Katja Zeppenfeld, Leiden University Medical Center:
Cardiomyopathy, Dilated
Tachycardia, Ventricular
Ventricular Fibrillation
Arrhythmias, Cardiac/etiology
Arrhythmias, Cardiac/physiopathology
Magnetic Resonance Imaging
3-Iodobenzylguanidine/diagnostic use
Sympathetic Nervous System/radionuclide imaging
Electrophysiologic Techniques, Cardiac
Biopsy
Genetic Testing
Echocardiography
Electrocardiography, Ambulatory
Exercise Test

Additional relevant MeSH terms:
Cardiomyopathies
Tachycardia
Ventricular Fibrillation
Tachycardia, Ventricular
Cardiomyopathy, Dilated
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes
Cardiomegaly
3-Iodobenzylguanidine
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals

ClinicalTrials.gov processed this record on August 16, 2017